Thomas Kim, JD, is the President and CEO of EpiVario Inc., where he has led the company through a seed round of financing and obtained proof-of-concept in animal behavioral models for small molecule drugs to treat PTSD, and also alcohol and drug addiction. He is a successful biotech corporate attorney and executive. Prior to EpiVario, he was the general counsel of Inovio Pharmaceuticals, where he was part of the executive team that grew the company into a NASDAQ listed, phase 3 development company. He is also a licensed patent attorney.
